Imidazoline derivatives having CB 1 -antagonistic activity

Details Imidazoline derivatives having CB 1 -antagonistic activity Imidazoline derivatives having CB 1 -antagonistic activity

2007-01-12

2009-02-24

Saeed, Kamal A (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S311100, C548S333500, C514S401000

Reexamination Certificate

active

07495108

ABSTRACT:
The present invention relates to 1,2,4-tri-substituted imidazoline derivatives, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said imidazoline derivatives, to methods for the preparation of these intermediates, to pharmaceutical compositions containing one or more of these imidazoline derivatives as active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders. The compounds have the general formula (I)wherein the symbols have the meanings given in the specification.

REFERENCES:
patent: 5952535 (1999-09-01), King et al.
patent: 6960601 (2005-11-01), Smith et al.
patent: 2004/0122074 (2004-06-01), Dow et al.
patent: 2004/0235854 (2004-11-01), Kruse et al.
patent: WO 03/026647 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/078413 (2003-09-01), None
patent: WO 03/101969 (2003-12-01), None
http://www.norml.org/index.cfm?Group—ID=7282&wtm—format=print (2 pages).
http://www.mayoclinic.com/health/anorexia/DS00606/DSECTION=8.
Megard et al., “A co-culture based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation”, Brain Research, 927, 2002, 153-167.
fact sheet Alzheimers association, 2 pages.
http://www.mayoclinic.com/health/alzheimers-disease/DS00161/DSECTION=3.
http://www.medindia.net/patients/patientinfo/Alzheimers—treatment.htm.
Zips et al, “new anticancer agents: in vitro and in vivo”, in vivo, 2005, 19, 1-7.
Dyck et al., “Potent Imidazole and Triazole CB1Receptor Agonists Related to SR141716,” Bioorganic & Medicinal Chemistry Letters, vol. 14, Iss. 5, pp. 1151-1154 (2004).
Khanna et al., “Selective Cyclooxygenase-2 Inhibitors: Heteroaryl Modified 1, 2-Diarylimidazoles Are Potent, Orally Active Antiinflammatory Agents,” J. Med. Chem. 2000, 43, 3168-3185.
Lange et al, “Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3, 4-Diarylopyrazolines as Potent and Elective CB1Cannabinoid Receptor Antagonists,” J. Med. Chem., 204, 47, 627-643 (2003).
International Search Report for corresponding PCT Application No. PCT/EP2005/050680 (International Publication No. WO 2005/080345), Examiner I. Scruton-Evans, Nov. 16, 2005.
International Preliminary Report on Patentability for International Application No. PCT/EP/2005/050680 (International Publication No. WO 2005/080345), Examiner I. Scruton-Evans, Nov. 16, 2005.
Co-Pending U.S. National Stage Application to Josephus H.M. Lange et al., based on International Patent Application No. PCT/EP2005/050680, filed Aug. 15, 2006.

Affiliated with

Also associated with

Rating

Imidazoline derivatives having CB 1 -antagonistic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazoline derivatives having CB 1 -antagonistic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazoline derivatives having CB 1 -antagonistic activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4096152